Clinical Trials Sponsored by Radicle Science

Total 19456 results

Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

Chronic Hepatitis B

United States, Hong Kong, Korea, Republic of, Taiwan, United Kingdom, Canada, New Zealand, Italy
Gilead Sciences

Withdrawn

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
Gilead Sciences

Terminated

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-hodgkin's Lymphoma | Small Lymphocytic Lymphoma

United States
Gilead Sciences

Completed

Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

Pancreatic Neoplasms

United States, Germany, Hungary, Netherlands
Gilead Sciences

Completed

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

Pancreatic Cancer

United States
Gilead Sciences

Withdrawn

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer
Gilead Sciences

Withdrawn

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Diffuse Large B-cell Lymphoma | NHL | Non Hodgkin's Lymphoma | Aggressive NHL

United States
Gilead Sciences

Unknown

Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma

Lymphoma

Switzerland, United States, Italy, Sweden, Austria
Gilead Sciences

Completed

Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer

Pancreatic Cancer

United States
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

Primary Sclerosing Cholangitis

United States, Canada, United Kingdom, Austria
Gilead Sciences

Completed

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

HIV Infections | HIV

Canada, United States, Spain, Puerto Rico, France, Switzerland, Australia, Germany, United Kingdom, Sweden, Brazil, Austria, Thailand, Netherlands, Belgium, Dominican Republic, Portugal, Italy, Denmark, Mexico
Gilead Sciences

Terminated

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

Previously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal Adenocarcinoma

United States
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin Lymphoma | Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)

Japan
Gilead Sciences

Completed

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin's Lymphoma

United States
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Diabetic Kidney Disease

United States
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function (HI)

Nonalcoholic Steatohepatitis (NASH)

United States
Gilead Sciences

Completed

Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment

Hepatitis B Virus

United States, Germany, New Zealand
Gilead Sciences

Terminated

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Non-FL Indolent Non-Hodgkin's Lymphoma

United States, Canada
Gilead Sciences

Completed

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants

HIV-1 Infection

United States
Gilead Sciences

Completed

Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)

Atrial Fibrillation

United States, Italy, Poland, Germany, Israel, Netherlands, United Kingdom
Gilead Sciences

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

HIV-1 Infection

United States, France, Austria, Germany
Gilead Sciences

Completed

Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection

Hepatitis C Virus Infection

United States, Belgium, Italy, United Kingdom
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Hepatitis C Virus Infection

United States, Puerto Rico
Gilead Sciences

Completed

Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol

HCV Infection

New Zealand
Gilead Sciences

Completed

Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

HIV-1 Infection

Spain, France, United States, Germany, Italy
Gilead Sciences

Completed

A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)

HIV

United States
Gilead Sciences

Completed

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Myelofibrosis

United States
Gilead Sciences

Completed

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GAMMA-1)

Gastric Adenocarcinoma

Spain, United States, United Kingdom, Turkey, France, Germany, Chile, Australia, Colombia, Czechia, Belgium, Hungary, Italy, Peru, Poland, Romania
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

Lupus Membranous Nephropathy

United States
Gilead Sciences

Terminated

Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults (Japanese AML)

Acute Myeloid Leukemia | Hematologic Malignancy

Japan
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection

Hepatitis C Virus Infection

Taiwan
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection

Chronic HCV Infection

China, Korea, Republic of, Taiwan
Gilead Sciences

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

HIV-1 Infection

Spain, United Kingdom, Italy, France, Belgium
Gilead Sciences

Completed

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Hepatitis C Virus Infection

Egypt
Gilead Sciences

Completed

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

HIV-1 Infection

United States
Gilead Sciences

Terminated

Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib

B-cell Malignancies

Spain, Czechia
Gilead Sciences

Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

HIV-1 Infection

United States, Spain, United Kingdom, Netherlands, Germany, Canada, Sweden, Switzerland, Italy, Belgium, Puerto Rico, France
Gilead Sciences

Completed

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

HIV-1 Infection

Spain, United Kingdom, Sweden, Germany, United States, France, Belgium, Ireland, Italy, Denmark, Puerto Rico, Canada
Gilead Sciences

Completed

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

HIV

United States, New Zealand
Gilead Sciences

Terminated

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States
Gilead Sciences

Terminated

Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

Chronic Lymphocytic Leukemia

United States, France, United Kingdom, Germany, Italy
Gilead Sciences

Completed

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Non-Alcoholic Steatohepatitis (NASH)

United States, Canada
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

Hepatitis C Virus Infection

United States, Italy, United Kingdom, Germany, Belgium, Russian Federation, New Zealand, Australia
Parion Sciences

Completed

An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness

Sjogren's Syndrome | Xerostomia

United States
Gilead Sciences

Completed

Selonsertib in Adults With Pulmonary Arterial Hypertension (ARROW)

Pulmonary Arterial Hypertension

Spain, United Kingdom, United States, Netherlands, Germany, Canada, France, Italy
Gilead Sciences

Terminated

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Liver Fibrosis Due to NASH

United States, Spain, France, Canada, Germany, Italy, Puerto Rico, United Kingdom, Belgium
Alimera Sciences

Unknown

Iluvien Registry Safety Study (IRISS)

Chronic Diabetic Macular Oedema Considered Insufficiently Responsive to Available Therapies

United States
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

India
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2)

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

Hepatitis C Virus Infection

New Zealand

3

Subscribe